Shares of AstraZeneca plc (NYSE:AZN) have earned an average recommendation of “Buy” from the twenty brokerages that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.96.
A number of analysts recently commented on the company. ValuEngine downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Pareto Securities raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, April 29th. Finally, Argus increased their price target on AstraZeneca to $50.00 and gave the company a “buy” rating in a research report on Wednesday.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC grew its holdings in AstraZeneca by 8.7% during the second quarter. Commonwealth Equity Services LLC now owns 137,225 shares of the company’s stock valued at $5,664,000 after purchasing an additional 10,933 shares during the period. OppenheimerFunds Inc. grew its holdings in AstraZeneca by 141.3% during the first quarter. OppenheimerFunds Inc. now owns 4,105,290 shares of the company’s stock valued at $165,977,000 after purchasing an additional 2,403,920 shares during the period. Parametric Portfolio Associates LLC grew its holdings in AstraZeneca by 6.0% during the first quarter. Parametric Portfolio Associates LLC now owns 2,606,557 shares of the company’s stock valued at $105,383,000 after purchasing an additional 147,559 shares during the period. Greenleaf Trust grew its holdings in AstraZeneca by 2.4% during the second quarter. Greenleaf Trust now owns 22,103 shares of the company’s stock valued at $912,000 after purchasing an additional 527 shares during the period. Finally, Moors & Cabot Inc. grew its holdings in AstraZeneca by 23.0% during the second quarter. Moors & Cabot Inc. now owns 14,863 shares of the company’s stock valued at $615,000 after purchasing an additional 2,783 shares during the period. 18.42% of the stock is owned by institutional investors and hedge funds.
Shares of AZN traded up $0.16 on Friday, reaching $44.34. 1,495,500 shares of the company’s stock traded hands, compared to its average volume of 3,958,019. The company has a current ratio of 0.95, a quick ratio of 0.75 and a debt-to-equity ratio of 1.19. The stock has a market cap of $111.90 billion, a PE ratio of 25.63, a PEG ratio of 1.51 and a beta of 0.52. The stock’s 50 day simple moving average is $42.25 and its two-hundred day simple moving average is $40.37. AstraZeneca has a 52-week low of $35.30 and a 52-week high of $45.28.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.43. The company had revenue of $5.72 billion during the quarter, compared to the consensus estimate of $5.57 billion. AstraZeneca had a return on equity of 35.83% and a net margin of 9.38%. AstraZeneca’s revenue was up 10.9% on a year-over-year basis. During the same period last year, the business posted $0.69 earnings per share. Analysts forecast that AstraZeneca will post 1.79 earnings per share for the current year.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.